Review Article

Adverse Drug Reactions of Levofloxacin in the Management of Pneumonia: A Pharmacovigilance-Based Review

Prajakta.A.Shingade*, Akash.P.Jadhav, Dr.Prakash.D.Jadhav, Gaurav.S.Potdar, Pranav.V.Pawar, Tejas.J.Vanjare, Pratiksha.B.Bhosale, Neha.S.Pawar
Yashoda Technical Campus, College of Pharmacy, Satara, Dist- Satara, Maharashtra, India.
***Corresponding author's E-mail:** shingadeprajakta30@gmail.com

Received: 06-03-2026; **Revised:** 18-05-2026; **Accepted:** 25-05-2026; **Published online:** 20-06-2026.

ABSTRACT

Effective antibiotic therapy is necessary for the best management of pneumonia, which is still a major source of morbidity and mortality globally. Because of its superior bioavailability and lung tissue penetration, levofloxacin, a broad-spectrum fluoroquinolone, is frequently recommended to treat pneumonia that is acquired in hospitals and the community. The safety profile of levofloxacin is the main topic of this review, with a focus on adverse drug reactions (ADRs) in patients with pneumonia. Gastrointestinal disorders, impacts on the central nervous system, and dermatological reactions are among the frequently reported adverse drug reactions (ADRs), according to data from clinical studies, pharmacovigilance databases, and published literature. But there have also been reports of severe adverse drug reactions (ADRs), especially in older patients, including QT interval prolongation, tendon problems, hepatotoxicity, dysglycemia, and hypersensitivity responses and people with co-occurring disorders. The review also emphasizes the importance of pharmacovigilance in the early identification, evaluation, and mitigation of hazards associated with drugs. To optimize treatment benefits while reducing potential risks, careful patient selection, dose adjustment, and ongoing monitoring are crucial. Overall, levofloxacin is still a useful treatment for pneumonia, but its usage requires careful safety monitoring to guarantee sensible and secure clinical practice.

Keywords: Levofloxacin; Hepatotoxicity; Pneumonia; Adverse Drug Reactions (ADRs); Fluoroquinolones; Pharmacovigilance; Drug Safety; QT Prolongation; Tendon Rupture; Dysglycemia.

INTRODUCTION

Pneumonia continues to be a major global source of morbidity and mortality, especially in children, the elderly, and people with impaired immune systems.[1] It is characterized by inflammation of the lung parenchyma, mostly affecting the alveoli, which fill with pus or fluid, impairing gas exchange and causing respiratory discomfort.[2]Numerous pathogens, including bacteria, viruses, and fungi, can cause the illness; bacterial pneumonia is the most prevalent and clinically relevant type that necessitates antibiotic treatment.[3]

Levofloxacin has been widely accepted as one of the antibacterial medicines used to treat pneumonia because of its broad-spectrum activity, good oral absorption, and efficient penetration into lung tissues.[4,5] Levofloxacin, a member of the fluoroquinolone class, works against bacteria by blocking topoisomerase IV and bacterial DNA gyrase, which stops cell division and DNA replication.[5] It is a recommended option for the treatment of both community-acquired and hospital-acquired pneumonia due to its pharmacokinetic and pharmacodynamic characteristics.[4]

Levofloxacin has been linked to a number of adverse drug reactions (ADRs) despite its clinical efficacy. These ADRs can range from minor gastrointestinal issues to severe and potentially fatal conditions like QT interval prolongation, tendon rupture, hepatotoxicity, and effects on the central nervous system.[6,7] Patient age, comorbidities, renal function, and concurrent drug use are some of the factors that affect the frequency and severity of these reactions.[6]

In this regard, pharmacovigilance is essential for identifying, evaluating, and preventing adverse drug reactions (ADRs) linked to levofloxacin treatment.[8,9] In order to guarantee patient safety, ongoing monitoring via national and international reporting systems aids in the discovery of new safety issues and supports regulatory decision-making.[8]

With a focus on their clinical significance, underlying processes, and the value of pharmacovigilance in encouraging safe and sensible drug use, this review attempts to give a thorough summary of the adverse drug events linked to levofloxacin in pneumonia patients.

METHODS

Study plan:

In order to assess the adverse drug reactions (ADRs) linked to levofloxacin in the treatment of pneumonia, this study is a narrative review that focuses on clinical evidence and pharmacovigilance data.[10,11]

Data sources and methods of search:

Using electronic databases such as PubMed, Google Scholar, ScienceDirect, and SpringerLink, a thorough literature search was conducted.[12] Keywords including "levofloxacin," "pneumonia," "adverse drug reactions," "fluoroquinolones," and "pharmacovigilance" were used to find pertinent publications published between 2000 and 2025. The search was narrowed down and retrieval accuracy was increased by using boolean operators (AND, OR).[12]

Inclusion standards:

Clinical studies, review articles, and peer-reviewed research articles[13]

Research on levofloxacin's adverse drug reactions in pneumonia patients[14]

WHO databases, pharmacovigilance reports, and regulatory safety bulletins published in English[15]

Exclusion standards:

Research unrelated to levofloxacin or pneumonia

Unpublished data or duplicate articles

Articles with inadequate safety or ADR information[13]

Data analysis and extraction:

The kind and frequency of adverse drug reactions (ADRs), patient characteristics, risk factors, and clinical outcomes were among the pertinent data that were taken from particular research.[14,16] Additionally, data from national reporting systems and pharmacovigilance databases like WHO-UMC were examined.[15] The gathered information was methodically examined and classified according to the organ systems impacted and the intensity of the reactions.[16]

Synthesis of data:

A through summary of levofloxacin's safety profile was produced by qualitatively synthesizing the results.[10] Finding frequently reported adverse drug reactions (ADRs), major adverse events, and risk variables linked to higher vulnerability in pneumonia patients were prioritized.[14,16]

RESULT AND DISCUSSION

According to the reviewed literature, levofloxacin's broad-spectrum antibacterial action, superior bioavailability, and efficient penetration into lung tissues make it a popular treatment for pneumonia.[17,18] According to clinical data, it offers notable treatment advantages for both hospital-acquired and community-acquired pneumonia, improving patient outcomes.[19]

Levofloxacin has been linked to a variety of adverse drug reactions (ADRs) in numerous trials despite its effectiveness.[20] Gastrointestinal ADRs, such as nausea, vomiting, diarrhea, and discomfort in the abdomen, are the most commonly reported. Although these effects are usually minimal, patient compliance may be impacted.[20,21] Effects of the central nervous system (CNS), including headache, lightheadedness, sleeplessness, and disorientation, are also frequently observed, especially in older patients and those with poor health[21,22]

Because levofloxacin has been linked to QT interval prolongation, which can cause severe arrhythmias in vulnerable people, cardiovascular safety is still a major worry.[23] Patients with electrolyte imbalances, pre-existing cardiac diseases, or concurrent drugs known to impair cardiac conduction are at higher risk.[23,24]

The harmful effects of fluoroquinolone antibiotics on the musculoskeletal system, such as tendinitis and tendon rupture, are severe. [22,24]Even though they are uncommon, these responses have the potential to cause major problems and are more common in older patients, those receiving corticosteroid medication, and people who have been exposed to drugs for an extended period of time.[24]

Additional documented adverse drug reactions (ADRs) include renal problems like high serum creatinine, hepatic effects like elevated liver enzymes and few occurrences of hepatotoxicity, and metabolic disorders including hypoglycemia and hyperglycemia, especially in diabetic individuals.[22,25]There have also been reports of hypersensitivity reactions ranging from minor skin rashes to severe allergic reactions.[21]

Numerous patient-related factors, such as age, renal function, comorbid diseases, and concurrent medication therapy, affect the incidence of adverse drug reactions.[20,25] Patients with pneumonia are especially susceptible because of conditions including hypoxia, dehydration, and polypharmacy, which can change how drugs are metabolized and raise the risk of side effects[19]

These results emphasize the significance of cautious patient selection, dose modification, and ongoing monitoring during levofloxacin therapy from a clinical standpoint. [18,22] Pharmacovigilance systems are essential for detecting, assessing, and preventing adverse drug reactions (ADRs), which enhances medication safety and treatment results.[26]

In conclusion, levofloxacin is still a useful treatment for pneumonia, but its use necessitates a careful evaluation of the risks and benefits, with a focus on reducing side effects through suitable clinical procedures.

CONCLUSION

Based on its broad-spectrum activity and superior lung penetration, levofloxacin is still a commonly used and effective fluoroquinolone antibiotic for the treatment of pneumonia. Although the majority of patients experience positive therapeutic outcomes, the medicine is linked to a variety of adverse drug reactions (ADRs) that differ in intensity, according to the reviewed literature

Common adverse drug reactions (ADRs) including gastrointestinal problems and effects on the central nervous system are usually moderate and controllable. However, the necessity for cautious use is highlighted by significant reactions such QT interval prolongation, tendon problems, hepatotoxicity, and metabolic abnormalities, particularly in high-risk populations like elderly individuals and those with concomitant illnesses. The results highlight how crucial it is to carefully choose patients, modify dosages, and keep an eye on them throughout treatment. Improving pharmacovigilance procedures is essential for early adverse effect detection and avoidance, which guarantees safer clinical usage.

In conclusion, levofloxacin's safety profile requires careful monitoring and prudent prescribing to maximize patient

outcomes and reduce potential dangers, even if it delivers substantial therapeutic benefits in the management of pneumonia.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. World Health Organization. Pneumonia Fact Sheet. Geneva: WHO; 2023.
2. Harrison's Principles of Internal Medicine. 21st ed. New York: McGraw-Hill; 2022.
3. Centers for Disease Control and Prevention. Pneumonia Overview. 2023.
4. Infectious Diseases Society of America, American Thoracic Society. Guidelines for the Management of Community-Acquired Pneumonia. Clin Infect Dis. 2019;68(6):e1–e68.
5. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill; 2018.
6. [8:19 pm, 27/04/2026] Prajakta: Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41(Suppl 2):S144–S157.
7. U.S. Food and Drug Administration. Fluoroquinolone Safety Labeling Changes. 2018.
8. World Health Organization. The Importance of Pharmacovigilance. Geneva: WHO; 2002.
9. Textbook of Pharmacovigilance. 2nd ed. New Delhi: CBS Publishers; 2017.
10. Textbook of Pharmacovigilance. 2nd ed. New Delhi: CBS Publishers; 2017.
11. World Health Organization. The Importance of Pharmacovigilance. Geneva: WHO; 2002.
12. Gusenbauer M, Haddaway NR. Which academic search systems are suitable for systematic reviews? Res Synth Methods. 2020;11(2):181–217.
13. PRISMA Statement. Preferred Reporting Items for Systematic Reviews and Meta-Analyses. 2020.
14. Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41(Suppl 2):S144–S157.
15. World Health Organization. WHO Programme for International Drug Monitoring.
16. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–1259.
17. [8:40 pm, 27/04/2026] Prajakta: Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill; 2018.
18. Infectious Diseases Society of America, American Thoracic Society. Guidelines for Community-Acquired Pneumonia. Clin Infect Dis. 2019;68(6):e1–e68.
19. World Health Organization. Pneumonia Fact Sheet. 2023.
20. Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41(Suppl 2):S144–S157.
21. Mandell LA, et al. Update of practice guidelines for pneumonia. Clin Infect Dis. 2007;44(Suppl 2):S27–S72.
22. Stahlmann R, Lode H. Safety considerations of fluoroquinolones. Clin Infect Dis. 2010;50(6):863–868.
23. U.S. Food and Drug Administration. Fluoroquinolone Drug Safety Communication. 2018.
24. van der Linden PD, et al. Fluoroquinolones and risk of Achilles tendon disorders. BMJ. 2002;324:1306–1307.
25. Chou HW, et al. Risk of severe dysglycemia with fluoroquinolones. Clin Infect Dis. 2013;57(7):971–980.
26. World Health Organization. The Importance of Pharmacovigilance. Geneva: WHO; 2002